Decreased Nonvertebral Fracture Incidence with Zoledronate Use For >3 Years: Post Hoc Analysis of an RCT

Area of Science:

• Gerontology
• Pharmacology
• Orthopedics

Background:

• Osteoporosis drug efficacy is typically assessed in short-term trials (up to 3 years).
• Long-term treatment effectiveness and potential changes over time are crucial for managing osteoporosis.
• Existing data from open trial extensions may be biased by patient attrition and lack placebo controls.

Purpose of the Study:

• To evaluate the anti-fracture efficacy of zoledronate over a 6-year period.
• To compare the efficacy of zoledronate in the first half versus the second half of the study.
• To determine if the effectiveness of osteoporosis treatment changes over longer durations.

Main Methods:

• A 6-year randomized controlled trial (RCT) involving 2000 osteopenic women aged over 65.
• Participants received either zoledronate or a placebo, administered every 18 months.
• Low participant withdrawal rates (3.6%) allowed for reliable comparison between study halves.

Main Results:

• Zoledronate significantly reduced non-vertebral fractures, with efficacy increasing in the second half of the study (Rate Ratio 0.40 vs. 0.83 in years 1-3).
• Similar trends were observed for total fragility fractures, including vertebral fractures (Rate Ratio 0.39 vs. 0.76 in years 1-3).
• Fracture rates per 1000 women-years decreased more substantially in the zoledronate group during years 4-6 compared to years 1-3.

Conclusions:

• The anti-fracture efficacy of zoledronate, and likely other anti-resorptive drugs, may be underestimated in standard short-term trials.
• Longer-term treatment with zoledronate appears to provide greater benefits in fracture prevention.
• These findings support the importance of extended treatment durations for osteoporosis management.